Skip to content
IP + Technology Law

Matthew Ruth

Associate
San Diego
[email protected]
858-707-4000
vcard iconDownload vCard

Overview

Matthew Ruth’s practice focuses on global patent prosecution and intellectual property portfolio management. He is also experienced with issues involving U.S. regulatory governance and antitrust.

Matthew assists clients in a range of technical fields including artificial intelligence, clean energy, electrical engineering, and electromechanical devices.

Matthew received his J.D. from the Sandra Day O’Connor College of Law at Arizona State University, where he worked with the Center for Law, Science, and Innovation on matters relating to the governance of emerging environmental technologies and artificial intelligence. Matthew also served as Senior Executive Editor of Jurimetrics, The Journal of Law, Science and Technology. During law school, Matthew worked with small business clients handling employment and IP contracting through the Innovation Advancement Clinic. He also worked as an advocate for small businesses in Washington D.C. on matters relating to antitrust, data privacy, and patents in the year prior to graduation. Upon graduation, Matthew received the Strouse Prize recognizing his contributions to the Law, Science, and Technology program at Arizona State.

Before attending law school, Matthew worked as an independent consultant specializing in geographic data analysis and interned as a telecommunications engineer.

Matthew joined the firm in 2022.

Education

  • Arizona State University - Sandra Day O'Connor College of Law (J.D., 2022), cum laude, Strouse Prize
  • McGill University (B.A. Psychology, 2017), Minor in Computer Science

Bar Admissions

  • State Bar of California

News & Insights

Articles

Latest Updates and News

Blog - Medical Devices & Procedures
Jun 2024
UK Proposes Approving Medical Devices Based on Approval in Other Countries
Device manufacturers may soon have access to a new framework for marketing and selling medical devices in the United Kingdom. On May 21, 2024, the UK Medicines and Healthcare products Regulatory Agency (MHRA) published a statement of intent for what could be a significant shift in policy: approval to market and sell medical devices based on prior approval from a comparable regulatory country (CRC). Medical devices approved under the new framework would be allowed into the UK market but would not receive the UK Conformity Assessed (UKCA) certification. Market availability would be determined based on the CRC approval.
Blog - Medical Devices & Procedures
Dec 2023
FDA Clears ABK Biomedical’s Eye90 Microspheres for Hepatocellular Carcinoma Treatment
ABK Biomedical successfully secured Breakthrough Device Designation from the FDA on December 5, 2023, for its Eye90 microspheres device, which is indicated for the treatment of unresectable Hepatocellular Carcinoma (HCC). The FDA’s Breakthrough Device Program is designed to speed up the development, assessment, review for premarket approval, 510(k) clearance, and de novo marketing authorization of medical devices “that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.” This program replaces the FDA’s Expedited Access Pathway and Priority Review for medical devices. Clearance of the Eye90 device was supported by ABK Biomedical’s recently initiated Route90 trial, an FDA Investigational Device Exemption-supported multicenter trial. The trial evaluated tumor response rates and the duration of response in patients living with unresectable HCC from treatment with Eye90 microspheres.
Blog - Medical Devices & Procedures
Jun 2023
FDA Updates Cybersecurity Guidance
Going forward, medical device approval will require the device maker to provide cybersecurity information to the FDA. Congress made this change by adding Section 524B to the Federal Food, Drug, and Cosmetic Act (FD&C Act) at the end of 2022, addressing concerns over the cybersecurity of medical devices. Risks from cybersecurity incidents involving medical devices may include “Health Insurance Portability and Accountability Act (HIPAA) violations, improper patient health assessments, miscalculated medication dosages, and other potentially fatal outcomes,” according to Lifesciences Intelligence.
Publications
Dec 2022
In Daily Journal Article, Daniel Hughes and Matthew Ruth Discuss Open-Source License Enforcement and Its Risks
Partner Daniel Hughes and associate Matthew Ruth authored “Open-Source License Enforcement; Risk to Companies” for The Daily Journal. In the article, Hughes and Ruth discuss how open-source software, which is...